Harrow Health Inc. (HROW)
| Bid | 24.12 |
| Market Cap | 871.75M |
| Revenue (ttm) | 199.61M |
| Net Income (ttm) | -17.48M |
| EPS (ttm) | -0.49 |
| PE Ratio (ttm) | -49.9 |
| Forward PE | 36.95 |
| Analyst | Strong Buy |
| Ask | 24.68 |
| Volume | 302,180 |
| Avg. Volume (20D) | 499,557 |
| Open | 24.21 |
| Previous Close | 24.09 |
| Day's Range | 23.56 - 24.98 |
| 52-Week Range | 9.86 - 59.23 |
| Beta | 0.45 |
About HROW
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma...
Analyst Forecast
According to 4 analyst ratings, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $61, which is an increase of 149.49% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings RampHarrow, Inc. is a speculative buy, with potential trading gains from the $20s to the $30s, and long-term growth prospects. The company reported strong Q4 growth, with an 84% revenue increase and impro...
2 weeks ago · businesswire.com
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial ResultsNASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024. ...
